Navigation Links
Cylex Announces Plan for Multi-Center Trial of ImmuKnow(R) Assay in South Korea
Date:8/28/2008

Seven Korean medical centers to collaborate on studies of immunosuppression

in kidney transplant patients and role of cell-mediated immunity

COLUMBIA, Md., Aug. 28 /PRNewswire/ -- "Cylex, Inc., in association with our Korean distributor, Sun Woo Biotech, is delighted to be able to announce our support for a major, multi-center trial of the ImmuKnow assay for cell-mediated immunity at seven highly respected medical institutions in the Republic of Korea," stated Brad Stewart, president of Cylex. "It is a critical goal for the Company to be able to demonstrate the effectiveness of the ImmuKnow assay in transplant populations of different ethnicities by working with specialized institutions around the world."

In the Republic of Korea, a multi-center consortium of kidney transplant centers will use the ImmuKnow assay to assess cell-mediated immunity of 238 patients between the ages of 15 and 60 who undergo an initial kidney transplant and who are randomly assigned to receive either triple immunosuppressive therapy (tacrolimus + mycophenolate mofetil + prednisone) or steroid-free immunosuppression (tacrolimus + mycophenolate mofetil only).

The seven institutions that will participate in this clinical trial include:

-- Samsung Medical Center (in Seoul)

-- KangNam St. Mary's Hospital (in Seoul)

-- Kyungpook National University Hospital (in Daegu)

-- Ajou University Hospital (in Suwon)

-- Daejeon St. Mary's Hospital (in Daegeon)

-- Soon Chun Hyang University Hospital (in Seoul)

-- Bong Seng Memorial Hospital (in Busan)

The ImmuKnow assay will be used to monitor all patients over a period of 36 months from initiation of treatment to assess the value of the assay predicting risk for organ rejection, in predicting risk for infection, and managing patients' immunosuppressed status with a goal of optimizing survival and minimizing organ rejection. Patients will have blood drawn and tested mon
'/>"/>

SOURCE Cylex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Independent Studies Report on Possible Roles for Cylexs Immune Cell Function Assay in Monitoring of Heart and Lung Transplant Recipients
2. Intercell Announces Initiation of Further Phase II Clinical Trial of V710 an Investigational Vaccine to Prevent S. aureus Infection
3. The University of Nottingham in the British Midlands Announces Breakthrough in Parkinsons Disease Research
4. Boston Scientific Announces Schedule for European Society of Cardiology Congress 2008
5. CRi Announces New Maestro(TM) EX In Vivo Imaging System with Improved Performance and an Affordable Price
6. XTENT Announces CUSTOM II Data Selected for Publication in EuroIntervention
7. Novavax Announces Favorable Results from Phase I/IIa Pandemic Influenza Vaccine Program
8. Omeros Announces Publication of Clinical Results for OMS103HP in Arthroscopy: The Journal of Arthroscopic and Related Surgery
9. Genmab Announces Upcoming Ofatumumab Studies
10. Indevus Pharmaceuticals Announces Completion of Enrollment in Phase III Trial of PRO 2000
11. Catalyst Pharmaceutical Partners Announces Publication of Animal Data Demonstrating Vigabatrin Effective for Weight Loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... , Aug. 21, 2014  eRelevance Corporation ( ... announced today that it has completed integration with ... for Plastic Surgery and Dermatology practices. ... value to healthcare practices using Nextech," stated ... Corporation. "Using information from the EMR we are ...
(Date:8/21/2014)... , Aug. 21, 2014 /CNW/ - Eisai Limited is ... introduction of the first-of-its-kind comic book available in ... has been designed specifically to educate children and their parents ... Canada affecting more than 300,000 Canadians. Eisai is ... care (hhc) , in which the patient is central – ...
(Date:8/21/2014)... 2014 /PRNewswire-iReach/ -- Inc. magazine today ... third straight year, No. 349 in Health on ... of the nation,s fastest-growing private companies. The list ... important segment of the economy—America,s independent entrepreneurs. Companies ... LinkedIn, Zillow, and many other well-known names gained ...
Breaking Medicine Technology:eRelevance Corporation Integrates with Nextech Electronic Medical Records 2Eisai Pleased to Support Canadian Epilepsy Alliance Comic Book that Teaches Children About Epilepsy 2Carolina's HME Named for Third Straight Year to Inc. Magazine's List of America's Fastest-Growing Private Companies--the Inc. 5000 2Carolina's HME Named for Third Straight Year to Inc. Magazine's List of America's Fastest-Growing Private Companies--the Inc. 5000 3
... 11, 2007 - New data,supporting the clinical development ... oral protease inhibitors for the,treatment of hepatitis C ... Annual Meeting of the European Association for the,Study ... In total, nine,abstracts related to telaprevir have been ...
... 11, 2007 /PRNewswire-FirstCall/ -- Vical,Incorporated today announced ... company's Vaxfectin(TM) adjuvant generated up,to 60-fold higher ... same dose in a recently completed study ... vaccine with,Vaxfectin(TM) also allowed a nearly 10-fold ...
Cached Medicine Technology:Vertex Pharmaceuticals Announces New Data for Investigational HCV,Protease Inhibitor Telaprevir to be Presented at 42nd Annual,Meeting of the European Association for the Study of the Liver,(EASL) 2Vertex Pharmaceuticals Announces New Data for Investigational HCV,Protease Inhibitor Telaprevir to be Presented at 42nd Annual,Meeting of the European Association for the Study of the Liver,(EASL) 3Vertex Pharmaceuticals Announces New Data for Investigational HCV,Protease Inhibitor Telaprevir to be Presented at 42nd Annual,Meeting of the European Association for the Study of the Liver,(EASL) 4Vertex Pharmaceuticals Announces New Data for Investigational HCV,Protease Inhibitor Telaprevir to be Presented at 42nd Annual,Meeting of the European Association for the Study of the Liver,(EASL) 5Vertex Pharmaceuticals Announces New Data for Investigational HCV,Protease Inhibitor Telaprevir to be Presented at 42nd Annual,Meeting of the European Association for the Study of the Liver,(EASL) 6Vical's Vaxfectin Adjuvant Achieves Dose-Sparing Effect With,Seasonal Influenza Vaccine 2Vical's Vaxfectin Adjuvant Achieves Dose-Sparing Effect With,Seasonal Influenza Vaccine 3Vical's Vaxfectin Adjuvant Achieves Dose-Sparing Effect With,Seasonal Influenza Vaccine 4Vical's Vaxfectin Adjuvant Achieves Dose-Sparing Effect With,Seasonal Influenza Vaccine 5
(Date:8/23/2014)... Cardiomyopathy (heart muscle disease) is ... myocardium (the heart muscle) for any reason, usually ... (breathlessness) and peripheral edema (swelling of the legs). ... dangerous forms of irregular heart beat and sudden ... is dilated cardiomyopathy. , Clinical trial report, “Cardiomyopathy ...
(Date:8/23/2014)... 23, 2014 The report “Polycarbonate ... & Forecasts to 2018” defines and segments the ... of the global revenue and consumption. It also ... polycarbonate resin market with analysis of trends, opportunities, ... and consumption and revenues are forecasted on the ...
(Date:8/23/2014)... 2014 According to the new ... Application and Geography - Regional Trends & Forecast ... Market with an analysis and forecast of value ... of electronic adhesives by applications and geography are ... market data tables and 26 figures spread through ...
(Date:8/23/2014)... August 23, 2014 A team of New ... last longer when preceded by surgery and delivered by an ... the new study. Click here to read it now ... the cases of mesothelioma patients who underwent hemithoracic ... radiotherapy dose to the shape of a tumor. Patients ...
(Date:8/23/2014)... August 23, 2014 On Monday, August ... a data breach suffered by Community Health Systems, ... compromise of 4.5 million records containing Personally Identifiable Information ... According to Mandiant, who was engaged to investigate the ... an advanced group of cyber attackers based in China, ...
Breaking Medicine News(10 mins):Health News:Cardiomyopathy (Heart Muscle Disease) Therapeutics Clinical Trials Market 2014 Analysis in a New Report Available at MarketOptimizer.org 2Health News:Cardiomyopathy (Heart Muscle Disease) Therapeutics Clinical Trials Market 2014 Analysis in a New Report Available at MarketOptimizer.org 3Health News:Cardiomyopathy (Heart Muscle Disease) Therapeutics Clinical Trials Market 2014 Analysis in a New Report Available at MarketOptimizer.org 4Health News:Polycarbonate Resin Market by Applications and Geography Projected to $18.3 Billion by 2018 - New Report by MarketsandMarkets 2Health News:Polycarbonate Resin Market by Applications and Geography Projected to $18.3 Billion by 2018 - New Report by MarketsandMarkets 3Health News:Polycarbonate Resin Market by Applications and Geography Projected to $18.3 Billion by 2018 - New Report by MarketsandMarkets 4Health News:Electronic Adhesives Market Poised to Reach $5.5 Billion by 2019 - New Report by MarketsandMarkets 2Health News:Electronic Adhesives Market Poised to Reach $5.5 Billion by 2019 - New Report by MarketsandMarkets 3Health News:New Study Links Hospital Experience and Prior Surgery with Mesothelioma Radiation Success, According to Surviving Mesothelioma 2Health News:This Time Prominent Hospital Group Falls Prey to Hackers Believed to be Based in China 2Health News:This Time Prominent Hospital Group Falls Prey to Hackers Believed to be Based in China 3Health News:This Time Prominent Hospital Group Falls Prey to Hackers Believed to be Based in China 4
... Reports’ has just enabled some valuable advice about chicken, which ... From virus to bacteria//, chicken seems to be hounded incessantly ... of 525 chickens, it found that nearly 83% of the ... or both. The bacteria are known to trigger diarrhea, cramping, ...
... study conducted by Asher Chanan-Khan, MD, Department of Medicine, ... for relapsed chronic lymphocytic leukemia (CLL) or diseases that ... response to the therapy. The results of this study ... Journal of Clinical Oncology. ,"Chronic lymphocytic ...
... a global initiative to develop a vaccine against malaria,// the ... ,The objective for the ‘Malaria Vaccine Technology Roadmap’ is ... fight Malaria by the year 2015. ,Malaria ... and rightly it is one of the oldest diseases in ...
... The popular hair-growth drug finasteride, taken by millions of ... antigen (PSA) test,// the standard screening test for prostate ... involving 308 men ranging in age from 40 to ... medical journal The Lancet and is scheduled to be ...
... was the focus of attention following an E. coli outbreak. ... with abdominal cramps, //fever and diarrhea. They were diagnosed with ... restaurants, operated by Yum Brands Inc in New Jersey have ... of the sick people reported that they had eaten from ...
... under Section 5 of the Insecticides Act, 1968 registers ... safety.// Toxicity and residues data generated under supervised trials ... (MRLs) by the Ministry of Health & Family Welfare ... Rules framed thereunder. The inspection of fruits and vegetables ...
Cached Medicine News:Health News:Hair-Growth Drug Artificially Lowers Psa Levels in Prostate Cancer Screening 2
An In Vitro Nucleic Acid Hybridization Assay with Signal Amplification using Microplate Chemiluminescence for the Qualitative Detection of Human Papillomavirus (HPV) Types 16, 18, 31, 33, 35, 39, 45,...
Rapid test for the presumptive identification of Candida albicans from culture media....
... is a system built ... and an imaging device ... zone size around an ... built-in expertise for detection ...
The best value and features offered in a complete EMR and Practice Management Solution...
Medicine Products: